A 72-year-old woman arrives with a tongue that ‘burns as if scalded'. Symptoms begin after dental treatments. After careful exclusion of local causes, dysaesthesia persists. She improves on a modest, individualised combination – titrated to address sleep, mood, and comorbidities – plus brief psychosocial support. In practice this is ordinary; in the literature it is almost invisible.
Burning mouth syndrome (BMS) exposes a wider problem in oral medicine: we have treated randomised controlled trials (RCTs) as the sole passport to guidance, yet many chronic oral/facial pain conditions in older, multimorbid patients do not fit pill-versus-placebo boxes. When our rules see only what RCTs can capture, effective chairside care disappears.
Keep RCTs as the spine of inference, but add the muscles of real-world evidence (RWE). BMS is heterogeneous and fluctuating. Dental treatments may trigger symptoms, but pathophysiology is multifactorial. Trials prefer narrow entry criteria, single agents, and short follow-up. Clinicians individualise low-dose combinations, integrate behavioural strategies with oral management, and allow time for neurosensory adaptation. A ‘no effect' result can reflect a mismatch between tidy methods and complex illness.
The blind spot extends beyond BMS: older adults remain underrepresented, distorting external validity.1,2 Responsible use of RWE is already described by NICE.3,4 What should we do now?
-
Build simple clinic registries with a minimum dataset (comorbidities, severity, sleep, mood, oral status, dose) captured during routine care; prioritise outcomes patients value – tolerating dentures, eating, socialising
-
Reward pragmatic designs: registry-based trials and N-of-1 series that permit titration and combination therapy
-
Stop excluding the people we treat: require justification for excluding older, multimorbid patients.
When guidance recognises only the classic trials, patients cycle through ‘evidence-based' yet ineffective single agents while multimodal regimens that help remain off-guideline. BMS is a case study; if journals systematically incorporate RWE alongside RCTs, we can close an evidence blind spot that harms older people.
During the preparation of this study, the authors employed the ChatGPT 5 Thinking (OpenAI) system to translate the manuscript from Japanese into English, improve readability, rephrase text where appropriate, and ensure proper grammar. Subsequently, the authors conducted a thorough review and made any necessary editorial revisions. The authors assume full responsibility for the final content presented in this publication.
References
O'Dowd A. Older people are excluded from clinical research, experts warn. BMJ 2025; DOI: 10.1136/bmj.r1719.
Pitkälä K H, Strandberg T E. Clinical trials in older people. Age Ageing 2022; DOI: 10.1093/ageing/afab282.
National Institute for Health and Care Excellence. Real-world evidence framework. 2022. Available at https://www.nice.org.uk/corporate/ecd9/chapter/overview (accessed 18 August 2025).
National Institute for Health and Care Excellence. NICE real-world evidence framework: update information. 2022–2025. Available at https://www.nice.org.uk/corporate/ecd9/chapter/update-information (accessed 18 August 2025).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Suga, T., Tu, T. & Toyofuku, A. Lessons from burning mouth syndrome. Br Dent J 239, 601–602 (2025). https://doi.org/10.1038/s41415-025-9335-6
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41415-025-9335-6